Comanche is a biopharmaceutical company focused on developing innovative siRNA molecules for the treatment of preeclampsia, a condition that poses risks to pregnancy and premature birth. Their goal is to provide safe and effective therapies that address the root cause of preeclampsia, allowing for natural pregnancy and fetal maturation. Comanche envisions a world where all pregnant women have access to evidence-based, cost-effective, and sustainable treatments for preeclampsia. By developing compounds designed to lower the risks of pregnancy and prematurity, Comanche aims to improve the health outcomes of pregnant women worldwide.